Ovarian Cancer

Joyce Nuqui Barlin, MD, shares the rationale for studying gotistobart plus pembrolizumab in patients with pretreated platinum-resistant ovarian cancer.

Relacorilant plus nab-paclitaxel displayed OS benefit irrespective of prior taxane exposure or taxane-free interval in platinum-resistant ovarian cancer.

Chiauranib plus weekly paclitaxel cut the risk of progression or death by 57% vs placebo plus paclitaxel in platinum-resistant or refractory ovarian cancer.

Nicholas Zorko, MD, PhD, discusses B7-H3 targeting in lung, GU, and gynecologic malignancies.

The FDA has published new sets of product-specific guidelines for investigating generic cancer treatments to guide proper evaluation of bioequivalence.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Poll results reflect some of the most anticipated presentations and fields of interest in gynecologic oncology at the 2026 ASCO Annual Meeting.

Discover which gynecologic cancer abstracts experts believe may affect evolving treatment paradigms and patient care discussions at ASCO 2026.

AVB-001 was tolerable and activated CD8+ and CD4+ T cells without regulatory T-cell expansion in platinum-resistant high-grade serous ovarian carcinoma.

The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

Alexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.

Bradley Monk, MD, FACOG, FACS, discusses the relevance of FRα, HER2, and PD-L1 expression in influencing decision-making in recurrent ovarian cancer.

Top experts discuss the most important takeaways and data to come out of this year’s SGO Annual Meeting on Women’s Cancer.

QLS5132 led to a 50% ORR and manageable safety in PROC, supporting CLDN6 as a promising ADC target in early-phase clinical development.

Early evidence suggests a dual bispecific strategy may be able to move the needle forward for patients with platinum-resistant ovarian cancer or endometrial cancer.

Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.

Mirvetuximab soravtansine plus carboplatin showed antitumor activity and a manageable safety profile in patients with recurrent platinum-sensitive ovarian cancer.

Bradley Monk, MD, discusses the final analysis of the phase 3 KEYNOTE-B96 trial in platinum-resistant recurrent ovarian cancer.

Alexander Olawaiye, MD, discusses the final overall survival data from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer.

Sofetabart mipitecan elicited strong antitumor activity in recurrent platinum-resistant high-grade serous ovarian cancer.

The novel ADC DB-1311/BNT324 was effective in cervical cancer and PROC, regardless of prior treatment or histology

Single-agent rezatapopt showed efficacy and safety irrespective of patients' platinum status, prior bevacizumab or PARP inhibitor exposure, or FRα expression.

Patients who received first-line niraparib as maintenance therapy had high resolution rates and low number of discontinuations due to hematologic PSEOIs.

With 1 year of additional follow-up, avutometinib plus defactinib showed durable efficacy with no new safety concerns in LGSOC.